Ultragenyx Pharmaceutical Inc. (RARE), a public biopharmaceutical company, has been making waves in the pharmaceutical industry with its commitment to developing innovative treatments for patients with rare and ultra-rare genetic diseases. Founded in 2010 and headquartered in Novato, California, Ultragenyx has been built on a foundation of determination and scientific brilliance.
The company's mission is clear: "Transform the treatment of rare and ultra-rare diseases by driving innovation and delivering value to patients" and over the past decade, Ultragenyx has made significant strides towards making this a reality. So far, the company has obtained approval for and launched three novel therapies, namely Crysvita (for X-linked hypophosphatemia and Tumor-Induced Osteomalacia), Mepsevii (for Mucopolysaccharidosis VII), and Dojolvi (for Long-Chain Fatty Acid Oxidation Disorders). These approvals mark important milestones for Ultragenyx, and more importantly, bring much needed hope and treatment options for patients living with these diseases.
In addition to these, Ultragenyx has built an extensive pipeline of promising drug candidates to address other devastating genetic diseases. It is known for applying its knowledge and unique infrastructure to manage the complexities of developing and delivering therapies to patients with rare genetic diseases. Ultragenyx is committed to patient centricity and maintains direct dialogues with patients and caregivers to understand their journey and challenges.
Ultragenyx's dedication to scientific innovation and patient welfare is reflected in its strategic collaboration with production partners and medical communities around the world. The company takes pride in its specialized teams, who strive to develop breakthrough therapies by pushing the boundaries of creativity and possibility.
Another notable achievement of Ultragenyx is its conscious effort to foster a culture of transparency, teamwork, courage, and relentless passion for creating the extraordinary. The company ardently promotes these values and has created a culture where employees can bring their best selves to work.
What elevates Ultragenyx in the pharmaceutical industry is not just the company's dedication to cultivating novel treatments for rare diseases, but also its commitment to operating sustainably and responsibly. With a keen eye for the future, this company is playing a significant role in transforming the face of the rare disease landscape, thereby bringing hope and improved quality of life to countless patients and families globally.